 Cognition Therapeutics Inc.s stock CGTX, is set to start trading Friday, after the New York-based biopharmaceutical company targeting treatments for central nervous systems disorders said its upsized initial public offering priced at 12 a share, in the middle of the expected range of between 11 and 13 a share. The company said it sold 3.77 million shares in the IPO, up from previous expectations of 3.35 million shares, to raise 45.2 million. 